Clinical Trials Logo
  1. Home
  2. Liver Transplantation
  3. NCT01696331
  4. Details
NCT01696331 Clinical Trial

Text Messaging for Adherence in Adolescent Liver Transplant Recipients

Liver Transplant Clinical Trial

Official title:
Impact of Text Messaging on Adherence in Adolescent Liver Transplant Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01696331
Other study ID # 25318
Secondary ID
Status Completed
Phase N/A
First received September 27, 2012
Last updated April 17, 2018
Start date September 2012
Est. completion date January 2013

Study information
Verified date April 2018
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Text message reminders will improve adherence to lab tests in adolescent liver transplant recipients.

Description:

Adolescent patients who received a liver transplant will be recruited to participate in receiving text message reminders for lab tests. They will be send de-identified messages according to their required lab schedule. The investigators will monitor their adherence to lab tests as well as medication and clinic visits. They will also have a questionnaire about their medical regimen before and at the end of the study.

Recruitment information / eligibility
Status Completed
Enrollment 42
Est. completion date January 2013
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender All
Age group 12 Years to 25 Years
Eligibility Inclusion Criteria:

- Patient >12 years

- Received liver transplant

- Followed by Stanford Liver Transplant Team

Exclusion Criteria:

- No personal cell phone

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Text Message Reminder
Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.

Locations
Country Name City State
United States Lucile Packard Children's Hospital Palo Alto California

Sponsors (1)
Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Adherence to lab tests One year
Secondary Texting responses Correspondence between actual completion of tests versus reported 1 year
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Recruiting NCT05051605 - Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
Recruiting NCT05940857 - Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
Completed NCT01598987 - Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. Phase 3
Active, not recruiting NCT05074160 - OCS Liver Perfusion (OLP) Post-Approval Registry
Completed NCT05087550 - Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
Recruiting NCT04836923 - LIFT Intervention in Liver Transplant Candidates N/A
Not yet recruiting NCT03666689 - Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
Not yet recruiting NCT06088758 - Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool N/A
Terminated NCT01230502 - Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation N/A
Completed NCT00171509 - Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients Phase 4
Not yet recruiting NCT06254248 - Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT06075745 - Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates Phase 2
Not yet recruiting NCT06280950 - Expanding Liver Transplant Immunosuppression Minimization Via Everolimus Phase 2
Completed NCT02057484 - A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
Active, not recruiting NCT03577431 - Liver Transplantation With Tregs at MGH Phase 1/Phase 2
Recruiting NCT06342557 - Transitional ePRO Diary Liver
Not yet recruiting NCT04265157 - Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry